Overview

OsteoCure Therapeutics is a Duke University spinout and JLABS company focused on developing advanced therapies to address critical unmet needs in bone health and regeneration. Leveraging cutting-edge research, the company specializes in novel combination products designed to accelerate bone healing, mitigate pain, improve patient outcomes, and reduce recovery times for those suffering from orthopedic injuries and conditions.

Operating within the rapidly evolving biotechnology and regenerative medicine industries, OsteoCure Therapeutics capitalizes on advancements in small molecule and drug delivery technologies to pioneer new treatment modalities. The industry’s growth is driven by an increasing aging population, rising incidence of orthopedic conditions, and escalating demand for effective, minimally invasive solutions. OsteoCure aims to position itself as a leader in this space through its flagship product, OCTA1, which is designed to promote superior bone regeneration and healing capabilities, while simultaneously reducing pain, which significantly enhances patient quality of life and clinical outcomes.